Sinusitis
Drug research and approvals for sinusitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 23 studies of sinusitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 23
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 23 recruiting on ClinicalTrials.gov ↗- Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Sinusitis)NCT07732699 · Phase 4 · Nader Shaikh · starts Oct 1, 2026
- Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional…NCT07149428 · Not reported · National Institute on Deafness and Other Communication Disorders (NIDCD) · starts Oct 1, 2026
- Opioid-Free Anesthesia in FESS: A Prospective ERAS StudyNCT07812389 · Not reported · Filiz Kaya · starts Aug 15, 2026
- Biologics in Chronic Rhinosinusitis With Nasal PolyposisNCT06824649 · Phase 4 · Medical University of South Carolina · starts Jun 3, 2026
- RhinAV_Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and RhinopharyngitisNCT07383493 · Not applicable · University Hospital, Clermont-Ferrand · starts Feb 25, 2026
- Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary CareNCT07359287 · Not applicable · University Hospital, Caen · starts Dec 1, 2025
- A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without…NCT07174115 · Phase 2 · Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · starts Aug 18, 2025
- Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis…NCT06850805 · Phase 3 · Optinose US Inc. · starts Jul 28, 2025
- The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult PatientsNCT06901297 · Phase 3 · Materia Medica Holding · starts Apr 3, 2025
- Topical Probiotic Sinus Irrigations for Treating Chronic SinusitisNCT05427695 · Phase 2 · University of Illinois Chicago · starts Feb 5, 2025
Drug Pipeline
21 approved, 12 in phase 3, 13 in phase 2, 12 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Amoxicillin, Levofloxacin anhydrous, Azithromycin, Epinephrine, Dupilumab, Clavulanic acid, Guaifenesin, Moxifloxacin, Telithromycin, Dextromethorphan, Pseudoephedrine, Cefuroxime axetil, Clarithromycin, Ciprofloxacin, Carbetapentane, Chlorpheniramine, Brompheniramine, Phenylephrine, Naphazoline, Oxymetazoline, Cefprozil anhydrous, (e)-
- Mometasone furoate
- Phase 3 Glucocorticoid receptor agonist
- Budesonide
- Phase 3 Glucocorticoid receptor agonist
- Dornase alfa
- Phase 3 DNA hydrolytic enzyme
- Fluticasone propionate
- Phase 3 Glucocorticoid receptor agonist
- Omalizumab
- Phase 3 Ig epsilon chain C region inhibitor
- Lidocaine
- Phase 3 Sodium channel alpha subunit blocker
- Beclomethasone dipropionate
- Phase 3 Glucocorticoid receptor agonist
- Reslizumab
- Phase 3 Interleukin-5 inhibitor
- Prednisone
- Phase 3 Glucocorticoid receptor agonist
- Rimegepant
- Phase 3 Calcitonin gene-related peptide type 1 receptor antagonist
- Acetylcysteine
- Phase 3 Glutathione precursor
- Pranlukast
- Phase 3 Cysteinyl leukotriene receptor 1 antagonist
- Itraconazole
- Phase 2 Cytochrome P450 51 inhibitor
- Betamethasone dipropionate
- Phase 2 Glucocorticoid receptor agonist
- Nitric oxide
- Phase 2 Soluble guanylate cyclase activator
- Acetaminophen
- Phase 2 Cyclooxygenase inhibitor
- Ibuprofen
- Phase 2 Cyclooxygenase inhibitor
- Oxycodone
- Phase 2 Mu opioid receptor agonist
- Esmolol
- Phase 2 Beta-1 adrenergic receptor antagonist
- Simvastatin
- Phase 2 HMG-CoA reductase inhibitor
- Labetalol
- Phase 2 Adrenergic receptor antagonist
- Benralizumab
- Phase 2 Interleukin-5 receptor subunit alpha inhibitor
- Etokimab
- Phase 2 Interleukin-33 binding agent
- Lactobacillus acidophilus
- Phase 2 Probiotic
- Xylitol
- Phase 2
- Silver
- Phase 1
- Bupivacaine
- Phase 1 Sodium channel protein type IV alpha subunit blocker
- Tobramycin
- Phase 1 70S ribosome inhibitor
- Vancomycin
- Phase 1 Peptidoglycan inhibitor
- Mupirocin
- Phase 1 Isoleucyl-tRNA synthetase inhibitor
Showing the 30 furthest along of 37 in trials.
How Its Trials Ended
454 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 114 whose ending is known, 41% met their primary endpoint, 6% missed it and 53% stopped early.
- Completed, result not reported19142%
- Ongoing9320%
- Status unknown5612%
- Met its primary endpoint4710%
- Stopped: other or unclear347%
- Stopped: enrollment or feasibility133%
- Missed its primary endpoint72%
- Stopped: lack of efficacy61%
- Stopped: funding41%
- Stopped: sponsor or business decision31%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA